Cargando…

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Cantini, Fabrizio, Niccoli, Laura, Matarrese, Daniela, Nicastri, Emanuele, Stobbione, Paolo, Goletti, Delia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/ https://www.ncbi.nlm.nih.gov/pubmed/32333918 http://dx.doi.org/10.1016/j.jinf.2020.04.017

Ejemplares similares

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
por: Goletti, Delia, et al.
Publicado: (2021)

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
por: Petrone, Linda, et al.
Publicado: (2021)

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
por: Cantini, Fabrizio, et al.
Publicado: (2017)

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
por: Niccoli, Laura, et al.
Publicado: (2018)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
por: Koh, Young Gue, et al.
Publicado: (2023)

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2019)

STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib
por: Olbrich, Peter, et al.
Publicado: (2023)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
por: Cantini, Fabrizio, et al.
Publicado: (2012)

Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
por: Cantini, Fabrizio, et al.
Publicado: (2013)

Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Cantini, Fabrizio, et al.
Publicado: (2009)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study
por: Francesconi, Paolo, et al.
Publicado: (2021)

Re: Remdesivir for the treatment of COVID-19 by Lee et al.
por: Beccacece, Alessia, et al.
Publicado: (2023)

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
por: Niccoli, Laura, et al.
Publicado: (2015)

HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis
por: Cantini, Fabrizio, et al.
Publicado: (2014)

Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome
por: Vita, Serena, et al.
Publicado: (2021)

Juvenile dermatomyositis‐associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy
por: Agud‐Dios, Manuel, et al.
Publicado: (2022)

Zika Virus Infection in the Central Nervous System and Female Genital Tract
por: Nicastri, Emanuele, et al.
Publicado: (2016)

Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
por: Mondi, Annalisa, et al.
Publicado: (2023)

Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients
por: Cantini, Fabrizio, et al.
Publicado: (2012)

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
por: Combe, Bernard, et al.
Publicado: (2019)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
por: Izumo, Takehiro, et al.
Publicado: (2021)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
por: Faria, Sofia, et al.
Publicado: (2023)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study
por: Belleudi, Valeria, et al.
Publicado: (2021)

COVID-19 effect on tuberculosis care in Sierra Leone: Are we in the recovery phase?
por: Buonsenso, D., et al.
Publicado: (2023)

Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature
por: Vita, Serena, et al.
Publicado: (2022)

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
por: Petrone, Linda, et al.
Publicado: (2021)

Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis
por: Tempestilli, Massimo, et al.
Publicado: (2021)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

COVID-19 effects on tuberculosis care in Sierra Leone
por: Buonsenso, D., et al.
Publicado: (2021)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Safety and Outcomes With Combination Therapy With Sarilumab and Baricitinib for Severe COVID-19 Respiratory Infection in Cancer Patients
por: Velez, Ana Paula, et al.
Publicado: (2023)

Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants
por: Alonzi, Tonino, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p9u9bl15q53apmi5grucb33m38